Method of making biologically active alpha-beta peptides
Described is a method of fabricating biologically active, unnatural polypeptides. The method includes the steps of selecting a biologically active polypeptide or biologically active fragment thereof having an amino acid sequence comprising α-amino acid residues, and fabricating a synthetic polypeptide that has an amino acid sequence that corresponds to the sequence of the biologically active polypeptide, but wherein about 14% to about 50% of the α-amino acid residues found in the biologically active polypeptide or fragment of step (a) are replaced with β-amino acid residues, and the α-amino acid residues are distributed in a repeating pattern.
1. A method of fabricating a biologically active, proteoloytic-resistant, unnatural polypeptide, the method comprising: fabricating a synthetic polypeptide that has an amino acid sequence that corresponds to a sequence of a biologically active polypeptide or fragment thereof, wherein
(i) in the synthetic polypeptide from about 14% to about 50% of the α-amino acid residues found in the biologically active polypeptide or fragment are replaced with analogous β-amino acid residues, wherein at least one of the β-amino acid residues is cyclically constrained via a ring encompassing its β 2 and β 3 carbon atoms;
(ii) in the synthetic polypeptide the β-amino acid residues and the α-amino acid residues are distributed in a pattern that repeats at least once, wherein the pattern of β-amino acid residues and α-amino acid residues is selected from the group consisting of (ααααααβ), (αααααβ), (ααααβ), (αααβ), and (ααβαβαβ).
2. The method of fabricating biologically active, unnatural polypeptides according to claim 1 , wherein in a folded structure adopted by the polypeptides, the repeating pattern disposes the β-amino acid residues in alignment along one side of the folded molecular structure when the unnatural polypeptides adopt a helical conformation.
3. The method of fabricating biologically active, unnatural polypeptides according to claim 1 , wherein the method comprises fabricating a synthetic polypeptide having from about 20 residues to about 50 residues.
4. The method of fabricating biologically active, unnatural polypeptides according to claim 1 , wherein the biologically active polypeptide or pharmaceutical salt thereof comprises between about 10 residues to about 100 residues and comprises at least two β-amino acid residues.
5. The method of fabricating biologically active, unnatural polypeptides according to claim 1 , wherein at least one of the β-amino acid residues is unsubstituted at its β 2 or β 3 carbon atoms.
6. A method of fabricating biologically active, unnatural polypeptides, the method comprising:
(a) selecting a biologically active polypeptide or biologically active fragment thereof having an amino acid sequence comprising α-amino acid residues; and
(b) fabricating a synthetic polypeptide that has an amino acid sequence that corresponds to the sequence of the biologically active polypeptide or fragment of step (a), wherein
(i) in the synthetic polypeptide between about 14% and about 50% of the α-amino acid residues found in the biologically active polypeptide or fragment of step (a) are replaced with β-amino acid residues, wherein at least one of the α-amino acid residues is replaced with at least one β-amino acid residue that is cyclically constrained via a ring encompassing its β 2 and β 3 carbon atoms;
(ii) in the synthetic polypeptide the β-amino acid residues and the α-amino acid residues are distributed in a repeating pattern; and
(iii) the synthetic polypeptide has a length of from about 10 residues to about 100 residues and comprises at least two β-amino acid residues;
wherein the synthetic polypeptide that is fabricated has a repeating pattern of α-amino acid residues and β-amino acid residues selected from the group consisting of (ααααααβ), (αααααβ), (ααααβ), (αααβ), and (ααβαβαβ).